



NEWS RELEASE

Oxford Immunotec Debuts Global Immunology Services Offering at World Vaccine Congress in Washington D.C.

4/18/2022

Leading developer of assays for T cell measurement introduces Certimmune global immunology services to support vaccine manufacturers in their phased clinical trials

WHAT: **Oxford Immunotec**, a PerkinElmer company, will exhibit at the World Vaccine Congress in Washington D.C. from April 18-21. This live, in-person event is the largest, most established meeting covering the entire vaccine value chain, from basic research to commercial manufacture. Oxford Immunotec will debut its **Certimmune**TM global immunology testing services at its booth (#800), which offer clinical, technical, operational and regulatory support to vaccine and immunotherapy manufacturers in facilitating immunology testing in support of their phased clinical trials.

HOW: Oxford Immunotec is a pioneer in the development of more reliable, high throughput, standardized tests for measuring the adaptive immune system. Built on Oxford Immunotec's two decades of experience in this area, the company's Certimmune services are available globally to help vaccine and immunotherapy manufacturers capture the highest quality data during their clinical trials and leverage it for regulatory submissions. Certimmune service offerings include:

- Assay design and development and validation
- High-volume testing implementation and operations

- Data interpretation and reporting
- Regulatory responses and quality management
- Global partner lab onboarding and monitoring
- Sample cryopreservation and long-term storage

WHY: “The COVID-19 pandemic has shown how critical T cells are in understanding immunity after viral infection and vaccination,” said Peter Wrighton-Smith, founder and chief executive officer of Oxford Immunotec. “Recognizing the challenges that many R&D teams face in performing or accessing high-throughput, high quality T cell assays, we formalized our Certimmune global immunology services to support vaccine and immunotherapy developers with all of their T and B cell immunoassay needs.”

MORE: In addition to T cell testing, Certimmune services allow vaccine and immunotherapy manufacturers to evaluate other cell types including B cells, antibodies and dendritic cells to gain a more holistic understanding of a patient’s adaptive immune response. The company is already supporting more than 20 clinical studies sponsored by vaccine developers and institutions with Certimmune services.

To learn more about the offering, visit www.certimmune.com

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately \$5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on [LinkedIn](#), [Twitter](#), [Facebook](#), [Instagram](#), and [YouTube](#).

###

Media Contacts

Chet Murray
 (781) 462-5126 | chet.murray@perkinelmer.com